NASDAQ:HALO Halozyme Therapeutics (HALO) Stock Price, News & Analysis → FW: 234x Gain (From Weiss Ratings) (Ad) Free HALO Stock Alerts $39.91 +0.09 (+0.23%) (As of 05/3/2024 ET) Add Compare Share Share Today's Range$39.79▼$40.7450-Day Range$37.81▼$41.9552-Week Range$29.85▼$45.00Volume902,786 shsAverage Volume1.21 million shsMarket Capitalization$5.07 billionP/E Ratio18.91Dividend YieldN/APrice Target$53.29 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Get Halozyme Therapeutics alerts: Email Address Halozyme Therapeutics MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.86 Rating ScoreUpside/Downside33.5% Upside$53.29 Price TargetShort InterestBearish6.55% of Float Sold ShortDividend StrengthN/ASustainability-1.12Upright™ Environmental ScoreNews Sentiment0.55Based on 8 Articles This WeekInsider TradingSelling Shares$1.20 M Sold Last QuarterProj. Earnings Growth23.91%From $3.43 to $4.25 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.86 out of 5 starsMedical Sector253rd out of 5,424 stocksBiological Products, Except Diagnostic Industry16th out of 909 stocks 3.4 Analyst's Opinion Consensus RatingHalozyme Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.86, and is based on 6 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageHalozyme Therapeutics has only been the subject of 4 research reports in the past 90 days. Previous Next 1.0 Short Interest Percentage of Shares Shorted6.55% of the float of Halozyme Therapeutics has been sold short.Short Interest Ratio / Days to CoverHalozyme Therapeutics has a short interest ratio ("days to cover") of 7.8.Change versus previous monthShort interest in Halozyme Therapeutics has recently increased by 4.44%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldHalozyme Therapeutics does not currently pay a dividend.Dividend GrowthHalozyme Therapeutics does not have a long track record of dividend growth. Previous Next 4.4 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreHalozyme Therapeutics has received a 65.83% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is false driven by its "Biopharmaceuticals" and "Medical technology engineering" products. See details.Environmental SustainabilityThe Environmental Impact score for Halozyme Therapeutics is -1.12. Previous Next 2.5 News and Social Media Coverage News SentimentHalozyme Therapeutics has a news sentiment score of 0.55. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.43 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 8 news articles for Halozyme Therapeutics this week, compared to 5 articles on an average week.Search InterestOnly 10 people have searched for HALO on MarketBeat in the last 30 days. This is a decrease of -38% compared to the previous 30 days.MarketBeat FollowsOnly 7 people have added Halozyme Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -36% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Halozyme Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,196,800.00 in company stock.Percentage Held by InsidersOnly 2.40% of the stock of Halozyme Therapeutics is held by insiders.Percentage Held by Institutions97.79% of the stock of Halozyme Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 4.4 Earnings and Valuation Earnings GrowthEarnings for Halozyme Therapeutics are expected to grow by 23.91% in the coming year, from $3.43 to $4.25 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Halozyme Therapeutics is 18.91, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 136.86.Price to Earnings Ratio vs. SectorThe P/E ratio of Halozyme Therapeutics is 18.91, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 198.93.Price to Earnings Growth RatioHalozyme Therapeutics has a PEG Ratio of 0.46. PEG Ratios below 1 indicate that a company could be undervalued.Price to Book Value per Share RatioHalozyme Therapeutics has a P/B Ratio of 63.35. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Colonial MetalsConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareThe latest flare-up between Israel and Palestinian militants has sent gold prices surging. Why? Because savvy investors know the endgame of the elites at play… Geopolitical crises breed uncertainty — and gold thrives on uncertainty. See why the elites are pouring billions into gold. About Halozyme Therapeutics Stock (NASDAQ:HALO)Halozyme Therapeutics, Inc., a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. It offers Hylenex recombinant, a formulation of rHuPH20 to facilitate subcutaneous (SC) fluid administration for achieving hydration to enhance the dispersion and absorption of other injected drugs in SC urography and to enhance resorption of radiopaque agents; rilpivirine, cabotegravir, and N6LS BNAB for the treatment of HIV; ocrelizumab for multiple sclerosis; XYOSTED, an injection for SC administration of testosterone replacement therapy; and ATRS-1902, a proprietary drug device combination product. The company also provides Herceptin (trastuzumab), Herceptin Hylecta, and Phesgo to treat breast cancer; Mabthera SC for the treatment of chronic lymphocytic leukemia; HYQVIA to treat primary immunodeficiency disorders; and DARZALEX for patients with amyloidosis, smoldering myeloma, and multiple myeloma. In addition, it offers Epinephrine Injection to treat allergic reactions; nivolumab+relatlimab and ANTI-TIM3 for the treatment of solid tumors; ARGX-117 for multifocal motor neuropathy; atezolizumab; nivolumab; afgartigimod; teriparatide injections; and OTREXUP, a SC methotrexate injection for adults with severe active rheumatoid arthritis and severe recalcitrant psoriasis, as well as children with active polyarticular juvenile idiopathic arthritis. Further, the company provides ATRS-1902 for adrenal crisis rescue; ARGX-113; and ARGX-117 to treat severe autoimmune diseases in multifocal motor neuropathy. Halozyme Therapeutics, Inc. was founded in 1998 and is headquartered in San Diego, California.Read More HALO Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart HALO Stock News HeadlinesApril 19, 2024 | insidertrades.comMichael J. Labarre Sells 10,000 Shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) StockApril 18, 2024 | insidertrades.comHalozyme Therapeutics, Inc. (NASDAQ:HALO) SVP Michael J. Labarre Sells 10,000 SharesMay 4, 2024 | Paradigm Press (Ad)Never use this word on your phone (FBI could be watching)This report sent a chill down my spine. Turns out, as part of their Jan. 6th investigation, the Feds are flagging Americans who typed these ordinary words as part of their banking transactions...May 3, 2024 | finance.yahoo.comHow Novo-Catalent Deal Affects Halozyme (HALO)?May 1, 2024 | americanbankingnews.comHalozyme Therapeutics (NASDAQ:HALO) Receives Buy Rating from HC WainwrightApril 30, 2024 | markets.businessinsider.comBuy Rating Affirmed for Halozyme on Strong Technology Prospects and Strategic PartnershipsApril 29, 2024 | msn.comSarepta Therapeutics Stock Shows Improved Technical StrengthApril 29, 2024 | msn.comHuonslab applies for clinical trial of hyaluronidase drugMay 4, 2024 | Paradigm Press (Ad)Never use this word on your phone (FBI could be watching)This report sent a chill down my spine. Turns out, as part of their Jan. 6th investigation, the Feds are flagging Americans who typed these ordinary words as part of their banking transactions...April 25, 2024 | prnewswire.comMahesh Krishnan Elected to Halozyme's Board of DirectorsApril 25, 2024 | markets.businessinsider.comCrossject reports audited financial results for 2023April 25, 2024 | investorplace.com3 Biotech Stocks That Could Be Multibaggers in the Making: April EditionApril 25, 2024 | americanbankingnews.comFY2026 EPS Estimates for Halozyme Therapeutics, Inc. (NASDAQ:HALO) Raised by AnalystApril 24, 2024 | americanbankingnews.comQ3 2025 Earnings Estimate for Halozyme Therapeutics, Inc. Issued By Zacks Research (NASDAQ:HALO)April 23, 2024 | finance.yahoo.comHalozyme to Report First Quarter 2024 Financial and Operating ResultsApril 19, 2024 | investing.comHalozyme Therapeutics CTO sells $768,390 in stockApril 17, 2024 | markets.businessinsider.comBuy Rating Affirmed for Halozyme on OCREVUS SC Prospects and Enhanze Technology PotentialApril 16, 2024 | markets.businessinsider.com9 Analysts Have This To Say About Halozyme TherapeuticsApril 10, 2024 | seekingalpha.comHalozyme's Strategic Partnerships Fueling Next-Gen TherapeuticsApril 10, 2024 | nasdaq.comValidea Detailed Fundamental Analysis - HALOApril 9, 2024 | stocknews.com3 Biotech Stocks to Buy in 2024April 8, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Halozyme (HALO) and MacroGenics (MGNX)April 4, 2024 | finance.yahoo.comIs Now The Time To Put Halozyme Therapeutics (NASDAQ:HALO) On Your Watchlist?March 29, 2024 | finance.yahoo.comMirum Pharmaceuticals (MIRM) Down 12.5% Since Last Earnings Report: Can It Rebound?March 29, 2024 | investorplace.comThe 3 Best Biotech Stocks to Buy in Q2 2024March 27, 2024 | finance.yahoo.comFate Therapeutics (FATE) Down 8% Since Last Earnings Report: Can It Rebound?March 16, 2024 | finance.yahoo.comHALO Apr 2024 35.000 putSee More Headlines Receive HALO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Halozyme Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/20/2024Today5/04/2024Next Earnings (Confirmed)5/07/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryBiotechnology Current SymbolNASDAQ:HALO CUSIP40637H10 CIK1159036 Webwww.halozyme.com Phone858-794-8889Fax858-704-8311Employees373Year Founded1998Price Target and Rating Average Stock Price Target$53.29 High Stock Price Target$72.00 Low Stock Price Target$40.00 Potential Upside/Downside+33.5%Consensus RatingModerate Buy Rating Score (0-4)2.86 Research Coverage7 Analysts Profitability EPS (Most Recent Fiscal Year)$2.11 Trailing P/E Ratio18.91 Forward P/E Ratio11.64 P/E Growth0.46Net Income$281.59 million Net Margins33.96% Pretax Margin42.01% Return on Equity248.20% Return on Assets19.13% Debt Debt-to-Equity Ratio17.89 Current Ratio6.64 Quick Ratio5.50 Sales & Book Value Annual Sales$829.25 million Price / Sales6.11 Cash Flow$3.23 per share Price / Cash Flow12.37 Book Value$0.63 per share Price / Book63.35Miscellaneous Outstanding Shares127,054,000Free Float124,005,000Market Cap$5.07 billion OptionableOptionable Beta1.26 Social Links 7 Stocks to Own Before the 2024 ElectionLooking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.Get This Free Report Key ExecutivesDr. Helen I. Torley M.B. Ch. B. (Age 61)M.R.C.P., President, CEO & Director Comp: $1.82MMs. Nicole LaBrosse (Age 41)Senior VP & CFO Comp: $849.36kDr. Michael J. LaBarre Ph.D. (Age 60)Senior VP & Chief Technical Officer Comp: $843.89kMr. Mark Snyder Esq.Senior VP & Chief Legal OfficerMs. Cortney Caudill M.B.A.Chief Operations OfficerMs. Tram BuiHead of Investor Relations & Corporate CommunicationsMs. Amy Marinne FoxSenior Vice President of Human ResourcesMs. Kristin SchwartzbauerHead of QualityMr. Gary GroteChief Commercial OfficerDr. Christopher Wahl M.B.A.M.D., Chief Business OfficerMore ExecutivesKey CompetitorsChina Biologic ProductsNASDAQ:CBPOMomenta PharmaceuticalsNASDAQ:MNTAExelixisNASDAQ:EXELRelay TherapeuticsNASDAQ:RLAYNovavaxNASDAQ:NVAXView All CompetitorsInsiders & InstitutionsBI Asset Management Fondsmaeglerselskab A SSold 112,058 shares on 5/3/2024Ownership: 0.011%GSA Capital Partners LLPBought 3,962 shares on 5/3/2024Ownership: 0.009%Callan Capital LLCBought 5,128 shares on 5/3/2024Ownership: 0.004%Central Pacific Bank Trust DivisionBought 2,820 shares on 5/3/2024Ownership: 0.002%Whittier Trust Co.Bought 672 shares on 5/3/2024Ownership: 0.001%View All Insider TransactionsView All Institutional Transactions HALO Stock Analysis - Frequently Asked Questions Should I buy or sell Halozyme Therapeutics stock right now? 7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Halozyme Therapeutics in the last twelve months. There are currently 1 hold rating and 6 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" HALO shares. View HALO analyst ratings or view top-rated stocks. What is Halozyme Therapeutics' stock price target for 2024? 7 Wall Street analysts have issued 12-month price objectives for Halozyme Therapeutics' stock. Their HALO share price targets range from $40.00 to $72.00. On average, they predict the company's share price to reach $53.29 in the next year. This suggests a possible upside of 33.5% from the stock's current price. View analysts price targets for HALO or view top-rated stocks among Wall Street analysts. How have HALO shares performed in 2024? Halozyme Therapeutics' stock was trading at $36.96 at the beginning of 2024. Since then, HALO stock has increased by 8.0% and is now trading at $39.91. View the best growth stocks for 2024 here. When is Halozyme Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 7th 2024. View our HALO earnings forecast. How can I listen to Halozyme Therapeutics' earnings call? Halozyme Therapeutics will be holding an earnings conference call on Tuesday, May 7th at 4:30 PM Eastern. Interested parties can register for or listen to the call using this link. How were Halozyme Therapeutics' earnings last quarter? Halozyme Therapeutics, Inc. (NASDAQ:HALO) issued its quarterly earnings results on Tuesday, February, 20th. The biopharmaceutical company reported $0.75 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.77 by $0.02. The biopharmaceutical company earned $230.04 million during the quarter, compared to analyst estimates of $235.25 million. Halozyme Therapeutics had a net margin of 33.96% and a trailing twelve-month return on equity of 248.20%. What ETFs hold Halozyme Therapeutics' stock? ETFs with the largest weight of Halozyme Therapeutics (NASDAQ:HALO) stock in their portfolio include First Trust NYSE Arca Biotechnology Index Fund (FBT), Future Fund Long/Short ETF (FFLS), Future Fund Active ETF (FFND), Invesco Biotechnology & Genome ETF (PBE), Virtus LifeSci Biotech Products ETF (BBP), Congress SMid Growth ETF (CSMD), BlackRock Future Innovators ETF (BFTR) and First Trust Nasdaq Pharmaceuticals ETF (FTXH). What guidance has Halozyme Therapeutics issued on next quarter's earnings? Halozyme Therapeutics updated its FY 2024 earnings guidance on Tuesday, February, 20th. The company provided EPS guidance of 3.550-3.900 for the period, compared to the consensus EPS estimate of 3.510. The company issued revenue guidance of $915.0 million-$985.0 million, compared to the consensus revenue estimate of $961.1 million. What is Helen Torley's approval rating as Halozyme Therapeutics' CEO? 12 employees have rated Halozyme Therapeutics Chief Executive Officer Helen Torley on Glassdoor.com. Helen Torley has an approval rating of 75% among the company's employees. What other stocks do shareholders of Halozyme Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Halozyme Therapeutics investors own include Xtrackers California Municipal Bond ETF (CA), Endologix (ELGX), BlackRock (BLK), Chipotle Mexican Grill (CMG), Micron Technology (MU), Gilead Sciences (GILD), Athabasca Oil (ATH), NIC (EGOV), Allergan (AGN) and AbbVie (ABBV). Who are Halozyme Therapeutics' major shareholders? Halozyme Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Allspring Global Investments Holdings LLC (0.55%), Allspring Global Investments Holdings LLC (0.55%), Principal Financial Group Inc. (0.45%), Congress Asset Management Co. MA (0.32%), Hodges Capital Management Inc. (0.25%) and WCM Investment Management LLC (0.24%). Insiders that own company stock include Connie Matsui, Helen Torley, James M Daly, Jean-Pierre Bizzari, Jeffrey William Henderson, Matthew L Posard, Michael J Labarre and Nicole Labrosse. View institutional ownership trends. How do I buy shares of Halozyme Therapeutics? Shares of HALO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. Does Halozyme Therapeutics have any subsidiaries? The following companies are subsidiares of Halozyme Therapeutics: Halozyme Holdings Ltd., Halozyme Inc., Halozyme Switzerland GmbH, and Halozyme Switzerland Holdings GmbH.Read More This page (NASDAQ:HALO) was last updated on 5/4/2024 by MarketBeat.com Staff From Our PartnersElon to Transform U.S. Economy? Porter & CompanyGlobal crypto currency reset (41 major banks signed up)Stansberry ResearchAutomatic Income (from home)Awesomely, LLCCould Your Accounts Be Frozen?Allegiance GoldThe Gold Grab of the CenturyColonial MetalsStock-Picking AI Predicts #1 Stock of 2024AltimetryThe only AI company you should be looking atBehind the MarketsThe A.I. story nobody is telling you (Read ASAP)TradeSmith Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Halozyme Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.